ALT
Altimmune·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
ALT fundamentals
Altimmune (ALT) released its earnings on Nov 6, 2025: revenue was 5.00K (YoY 0.00%), beat estimates; EPS was -0.21 (YoY +34.38%), beat estimates.
Revenue / YoY
5.00K
0.00%
EPS / YoY
-0.21
+34.38%
Report date
Nov 6, 2025
ALT Earnings Call Summary for Q3,2025
- Clinical Momentum: 24-week MASH resolution data drove FDA Phase III meeting; AUD trial enrollment completed 5 months early.
- Financial Strength: $211M cash, $127M raised YTD; R&D/G&A expenses aligned with clinical expansion.
- Strategic Differentiation: Dual-agonist mechanism vs. triple-agonist competitors; oral formulation in preclinical phase.
- Endpoint Innovation: FDA evaluating NITs as primary endpoints; AI biopsy validation underway for Phase III.
EPS
Revenue
Revenue & Expenses
ALT has released its 2025 Q3 earnings report, with revenue of 5.00K, reflecting a YoY change of 0.00%, and net profit of -19.01M, showing a YoY change of 16.77%. The Sankey diagram below clearly presents ALT's revenue sources and cost distribution.
Key Indicators
Altimmune (ALT) key financial stats and ratios, covering profitability, financial health, and leverage.
Altimmune (ALT)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Altimmune (ALT)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Altimmune (ALT)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Altimmune (ALT) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Altimmune (ALT) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
What were the key takeaways from Altimmune's earnings call?What is Altimmune's latest dividend and current dividend yield?What were the key takeaways from Altimmune’s earnings call?What factors drove the changes in Altimmune's revenue and profit?What does Altimmune do and what are its main business segments?What is the revenue and EPS growth rate for Altimmune year over year?What guidance did Altimmune's management provide for the next earnings period?Did Altimmune beat or miss consensus estimates last quarter?
